A hospital group can intervene in four legal battles between pharmaceutical giants and US health officials over proposals to discount drugs as a rebate under a federal drug pricing program, a federal judge ruled.
340B Health, a group representing over 1,500 public and private nonprofit hospitals under the federal 340B Drug Pricing Program, sufficiently alleged an injury in fact for intervening in cases between the US Health Resources and Services Administration and drugmakers